The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 24, 2023

Filed:

Dec. 06, 2019
Applicant:

Zhejiang Doer Biologics Corporation, Hangzhou, CN;

Inventors:

Gaofeng Yao, Hangzhou, CN;

Yali Lu, Hangzhou, CN;

Zhenxing Zhou, Hangzhou, CN;

Yilin Fang, Hangzhou, CN;

Li'na Zhu, Hangzhou, CN;

Changkui Li, Hangzhou, CN;

Hongta Zhang, Hangzhou, CN;

Xiaofang Wen, Hangzhou, CN;

Jiali Dong, Hangzhou, CN;

Yanshan Huang, Hangzhou, CN;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); A61K 35/17 (2015.01); C12N 5/0783 (2010.01); C12N 15/62 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/28 (2013.01); A61K 35/17 (2013.01); A61K 47/68 (2017.08); A61P 35/00 (2018.01); C12N 5/0636 (2013.01); C12N 15/62 (2013.01); A61K 2039/505 (2013.01);
Abstract

The present disclosure relates to the field of biology, in particular, to an anti-CLD18A2 VHH. The present disclosure provides an anti-CLD18A2 VHH. A complementarity determining region (CDR) of the anti-CLD18A2 VHH includes CDR1-CDR3 having amino acid sequences as shown below: CDR1 having an amino acid sequence represented by one of SEQ ID NO. 4-11, CDR2 having an amino acid sequence represented by one of SEQ ID NO. 19-26, and CDR3 having an amino acid sequence represented by one of SEQ ID NO.33-39. The anti-CLD18A2 VHH of the present disclosure can specifically bind to the epitope on CLD18A2, and the corresponding fusion protein thereof has good specificity and affinity for CLD18A2, and has a noticeable tumor suppression effect.


Find Patent Forward Citations

Loading…